Following the success of monoclonal antibodies in the treatment of a variety of tumor diseases, current research is focused on identifying mABs to inhibit additional ICP axes besides the PD1-PD-L1 and CTLA4 axes and optimizing all of these therapies. Here, CTLA4 is linked to neoplasm.